PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has secured a contract to supply its LaNeo MDMA for a clinical trial at Yale University, highlighting its growing reputation in academic research circles. Additionally, the company plans to settle $100,000 in debt by issuing common shares, showcasing its strategic financial management.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
